T1	Participants 94 140	patients with advanced head and neck carcinoma
T2	Participants 354 442	patients with advanced head and neck squamous cell carcinoma or nasopharyngeal carcinoma
T3	Participants 444 554	Patients with locally advanced or metastatic head and neck squamous cell carcinoma or nasopharyngeal carcinoma
T4	Participants 730 774	One hundred and thirty-six eligible patients
T5	Participants 919 951	patients who received endostatin
T6	Participants 1352 1365	control group
T7	Participants 1382 1392	test group
T8	Participants 1566 1654	patients with advanced head and neck squamous cell carcinoma or nasopharyngeal carcinoma
